Home

DENNIS LANGER

CIK 1274225 · last filed 2026-08-28

DENNIS LANGER is a corporate insider who has filed 72 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider was granted $177.9K of QNRX on Aug 28, 2026. Across all open-market trades the lifetime net is −$10.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $807.0K across reported positions. 31 SEC filings were submitted jointly with MYRIAD GENETICS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$807.0K

Companies

10

Total Filings

72

Lifetime Open-Market Net

-$10.51M

Filer Profile

Reported Address
C/O PETER TSOFLIAS, BLANK ROME LLP
ONE LOGAN SQUARE, FL 9
PHILADELPHA, PA 19103
Related Filers
MYRIAD GENETICS INC — 31 joint filings, latest 2022-06-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
QNRX Director 56,243 $6.43 $361.6K $128.4K 8 2026-08-28
MYGN Director 106,802 $4.17 $445.4K -$9.94M 26 2022-06-30
BTX Director — $9.04 — $0 1 2021-12-10
Dicerna Pharmaceuticals Inc (DRNA) Delisted Director 77,042 $38.22 $2.94M -$697.1K 11 2019-06-21
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted Director — — — $0 3 2018-05-23
DCTH Director 0 $15.60 $0 $0 2 2015-06-12
Myrexis, Inc. (MYRX) Delisted Director — — — $0 3 2011-12-12
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Director 1,366 — — $0 13 2010-06-07
CYTOGEN CORP (CYTO) Delisted Director 0 $0.30 $0 $0 2 2008-05-09
PHARMACOPEIA INC (PCOP) Delisted Director — — — $0 1 2008-05-02

Recent Filings

72 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-28 QNRX Grant (A) +34,534 $177.9K EDGAR
2026-02-06 QNRX Grant (A) — $0 EDGAR
2025-10-15 QNRX Buy (P) +15,152 $128.6K EDGAR
2025-08-25 QNRX Grant (A) — $0 EDGAR
2025-06-02 QNRX Grant (A) — $0 EDGAR
2024-12-10 QNRX Grant (A) — $0 EDGAR
2024-06-10 QNRX Sell (S) −297 -$217 EDGAR
2024-06-07 — Notice (144) −297 -$218 EDGAR
2023-10-30 QNRX Grant (A) — $0 EDGAR
2022-06-30 MYGN — — $0 EDGAR
Showing 1–10 of 72
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.